Skip to content

Ultrasonography SWE for Hepatic Fibrosis Evaluation

Diagnostic Performance of Shear Wave Elastography for Fibrosis Evaluation: Preliminary Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02673411
Enrollment
140
Registered
2016-02-03
Start date
2016-03-03
Completion date
2017-01-16
Last updated
2021-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis

Keywords

elastography, ultrasonography

Brief summary

The purpose of this study is to measure diagnostic performance of ultrasound shear wave elastography to detect advanced hepatic fibrosis.

Detailed description

Hepatic fibrosis causes liver dysfunction and HCC. Since hepatic fibrosis is reversible dynamic condition, its monitoring is important to predict long term outcome and to determine treatment plan. The reference of standard to diagnose hepatic fibrosis is biopsy, but recently non-invasive method such as stiffness imaging has been drawing a lot of attention. In this study, ultrasound shear wave elastography will be performed and its diagnostic performance to detect advanced hepatic fibrosis (= \> F2) will be measured using histologic grade as a reference.

Interventions

ultrasound shear wave elastography is performed in GE ultrasound scanner according to guidelines of ultrasound elastography.

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* volunteers who agree to undergo US shear elastography OR * patients with chronic liver disease who are scheduled to undergo liver resection or liver parenchymal biopsy. AND * = or \> 18 years * sign informed consent

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
diagnostic performance to detect advanced hepatic fibrosis1 monthfrom ultrasound SWE to perform hepatic resection or percutaneous liver biopsy in patients (with histologic diagnosis)

Secondary

MeasureTime frameDescription
interobserver agreement of ultrasound SWE1 daytwo observers perform ultrasound SWE on the same day in volunteers.
agreement with MR elastography1 monthinterval between US and MR elastography in patients with available MR elastography
Technical success rate6 monthstechnical success or failure of US elastography using GE LOGIQ E9 scanner in ALL study population
Reliable measurement rate6 monthsreliable measurement rate (interquartile range of serial measurement/median LS value \<30%) in patients with technically successful US elastography

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026